WNT4, a secreted protein that suppresses male sexual differentiation, is thought to repress the biosynthesis of gonadal androgen in female mammals. An 18-year-old woman presented with primary amenorrhea and an absence of müllerian-derived structures, unilateral renal agenesis, and clinical signs of androgen excess -a phenotype resembling the Mayer-Rokitansky-Küster-Hauser syndrome and remarkably similar to that of female Wnt4 -knockout mice. A genetic evaluation revealed a loss-of-function mutation in the WNT4 gene. WNT4 appears to be important in the development and maintenance of the female phenotype in women, by means of the regulation of müllerian-duct formation and control of ovarian steroidogenesis.
the migration of mesonephric endothelial and steroidogenic cells, preventing the formation of malespecific coelomic blood vessels and the production of steroids. 4 Collectively, these data suggest that WNT4 normally functions to suppress the synthesis of gonadal androgen in females.
A previous search for clinically relevant WNT4 mutations in a large cohort of patients with abnormalities in sexual development was unsuccessful. 6 We describe a woman without structures derived from müllerian ducts (uterine and fallopian tubes) who had unilateral renal agenesis and clinical signs of androgen excess. Her phenotype resembles that of patients with the Mayer-Rokitansky-Küster-Hauser syndrome 7, 8 and is also strikingly similar to that of Wnt4 -knockout female mice. This constellation of findings prompted us to search for mutations in the WNT4 gene in this patient.
A woman who was 18 years 7 months old was referred for evaluation of primary amenorrhea. Thelarche and adrenarche had occurred at 12 years of age, and both breast and pubic-hair development had progressed normally. Physical examination revealed a normal weight (47 kg; standard-deviation score, ¡0.9 ), height (158 cm; standard-deviation score, ¡1.1), body-mass index ([the weight in kilograms divided by the square of the height in meters] 18.8; standard-deviation score, ¡0.6), and blood pressure (110/65 mm Hg); acne (requiring antiandrogen therapy); pubic hair of the adult-female type (Tanner stage 5); and mature female breasts (Tanner stage 5). The clitoral size was normal, but the vaginal introitus was small and short (0.5 cm). Laboratory examination revealed elevated levels of androstenedione (25. 4 were absent, both ovaries were of normal size but ectopic (retroperitoneal, above the iliac crest), and the right kidney was aplastic, with compensatory hypertrophy of the left kidney.
The study conformed to the guidelines of the institutional review board, and all determinations were conducted as part of diagnostic procedures approved by the institutional review board. Oral informed consent was obtained from all subjects.
mutational analysis of genomic dna
Genomic DNA was extracted from peripheralblood leukocytes from the patient, her mother and sister, and 100 ethnically matched control subjects (200 alleles; 50 male and 50 female subjects), and all five exons of the WNT4 gene were amplified by means of the polymerase chain reaction (PCR) with the use of a Qiagen DNA blood-and cell-culture kit. Sequences of the primers used to amplify the exons of WNT4 (GenBank accession number, NT_004610) and the gene for hepatocyte nuclear factor 1 b ( TCF2; GenBank accession numbers, U90279 and U90280-7) are available on request (Mycrosynth). SRY amplification was conducted as described previously. 9 Direct cycle sequencing of the PCR products was performed with the use of the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems) and analyzed with the use of the ABI Prism 310 Genetic Analyzer (Applied Biosystems).
expression studies
To study the functional implications of the mutation we identified, we first performed reverse-transcriptase PCR on WNT4 messenger RNA (mRNA) ectopically expressed in peripheral-blood leukocytes from control subjects. 10 Primer sequences and PCR-amplification conditions used for wildtype WNT4 complementary DNA (cDNA) are available on request. The wild-type cDNA was then subjected to PCR-mediated site-directed mutagenesis. 11 The sequence was verified as described above. Confluent cultures of a human ovarian adenocarcinoma cell line (OVCAR3, National Institutes of Health; American Type Culture Collection [ATCC], HTB-161), an adrenal adenocarcinoma cell line (H295R, National Cancer Institute; ATCC, CRL-2128), and renal 293T cells (ATCC, CRL-11268) were transfected with 10 µg of wild-type WNT4 DNA, 10 µg case report methods of mutant WNT4 DNA, or a combination of the two (molar ratio, 1:1) in 60-mm plates with the use of the TransFast transfection system reagent (Promega) according to the manufacturer's instructions. The ovarian adenocarcinoma cells, which express steroid receptors 12 and steroidogenic enzymes, 13 provide an in vitro model for evaluating the functional effects of WNT4. The influence of wild-type and mutant WNT4 on the expression of the steroidogenic enzymes 17 a -hydroxylase (GenBank accession number, NM_000102) and 3 b -hydroxysteroid dehydrogenase type 2 (GenBank accession number, 000198) and of the transcription factor hepatocyte nuclear factor 1 b (GenBank accession num- In Panel A, chromatograms obtained by direct sequencing of PCR products reveal a heterozygous substitution of G for A in exon 5 of the WNT4 gene in the patient, but not in a representative control subject or in the patient's mother or sister. Panel B shows the general structure of the WNT4 gene and protein and the location of the E226G mutation. The genomic organization is derived from published sequences (GenBank accession number, NT_004610). 3 The five exons are represented by boxes. The protein domains were identified with the use of the Eukaryotic Linear Motif Server (TNT Software). The position of the Xpress epitope is also depicted. Panel C shows the conservation among species of the sequence that was mutated in the WNT4 gene in our patient. Alignments were performed with the use of the Clustal W alignment program.
bers, U90279 and U90280-7) was studied by means of quantitative real-time PCR, performed with the use of an ABI 7000 Sequence Detection System (Applera Europe), and PCR products were quantified fluorometrically with the use of the SYBR Green Core Reagent kit. The reference mRNA cyclophilin was used to normalize the data. Western blot analysis was performed with the use of antiXpress (Invitrogen), an antibody that recognizes the epitope of the N-terminal Xpress peptide, according to the manufacturer's instructions. The activity of the steroidogenic enzymes was assessed by radioimmunoassays of progesterone (DPC Biermann) and 17-hydroxyprogesterone, androstenedione, and testosterone (CisBio International) in cell-culture medium after the addition of pregnenolone (100 ng per milliliter) as a precursor. Total protein content was assayed (BioRad protein assay).
In vivo labeling of WNT4 with tritiated palmitate was performed as described previously, 14 except that the assay was performed in cell extracts rather than in medium after immunoprecipitation of the protein 13 with the use of anti-Xpress antibody. Western blotting was performed to determine the degree of b -catenin stabilization with the use of a commercially available antibody against b -catenin (U.S. Biological). All experiments were performed in triplicate. u t a n t M u t a n t U n t r a n s f e c t e d
u t a n t M u t a n t U n t r a n s f e c t e d U n t r a n s f e c t e d U n t r a n s f e c t e d W i l d T y p e + M u t a n t W i l d T y p e M u t a n t U n t r a n s f e c t e d W i l d T y p e + M u t a n t W i l d T y p e M u t a n t U n t r a n s f e c t e d W i l d T y p e M u t a n t W i l d T y p e + M u t a n t U n t r a n s f e c t e d , wild-type WNT4 , or both with the use of primers specific for the subcloned 540-bp WNT4 reverse-transcriptase-PCR product alone. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a protein expressed in most tissues, was used as a control. As shown in Panel C, the mutant WNT4 failed to inhibit steroidogenesis, with a consequent increase in androgen production in ovarian cells. Levels of progesterone, 17-hydroxyprogesterone, androstenedione, and testosterone were measured in the medium of ovarian adenocarcinoma cells in the presence
Direct sequencing of PCR-amplified exonic fragments revealed a heterozygous substitution of guanine for adenine in exon 5 of the WNT4 gene, leading to the Glu226Gly (E226G) missense mutation of the WNT4 protein ( Fig. 1A and 1B) . Glutamate 226 is a WNT4 residue conserved among human, mouse, rat, chicken, zebra fish, and lancelet species (Fig. 1C) . The absence of the mutation in the DNA of the patient's mother and sister and 100 control subjects (200 alleles, data not shown) indicates that this substitution was either inherited from her father (whose DNA was not available for analysis) or a spontaneous event, and that it is not a common polymorphism. No mutation was found in the TCF2 gene, which encodes the transcription factor hepatocyte nuclear factor 1 b that is crucial for the development of the kidneys and pancreas 15 (data not shown). To determine the functional consequences of the rearrangement, we studied the expression of the steroidogenic enzymes 17 a -hydroxylase and 3 b -hydroxysteroid dehydrogenase type II and hepatocyte nuclear factor 1 b . The mutant WNT4 was unable to suppress the expression of the steroidogenic enzymes in ovarian adenocarcinoma cells ( Fig. 2A) and adrenal adenocarcinoma cells (data not shown). In renal cells, the mutant WNT4 appeared to favor the expression of the short form of TCF2, which is devoid of the transactivation domain (data not shown). The effects were not due to differences in the expression of WNT4 (Fig.  2B) . The lack of inhibition of the expression of steroidogenic enzymes resulted in increased steroid production in ovarian adenocarcinoma cells transfected with the mutant WNT4 (Fig. 3) , as also appeared to be the case in the ovaries of our patient. The absence of the mutant WNT4 in the medium of cultured ovarian cells (Fig. 3A) suggests that the mutant WNT4 remains trapped within the cells. Since proper processing of WNT proteins requires lipid-mediated modification, 16 we evaluated the extent of the attachment of radiolabeled palmitate to wild-type and mutant WNT4 in ovarian adenocarcinoma cells. The E226G mutant was inefficiently palmitoylated and, when transfected together with the wild type, partially prevented the palmitoylation of the transfected wild-type WNT4 (Fig. 3B ). The differences in lipid modification are not due to differences in the amount or stability of the protein (Fig. 3C) . Evidence that the mutation did cause a defect in the WNT4 signal-transduc- U n t r a n s f e c t e d U n t r a n s f e c t e d U n t r a n s f e c t e d W i l d t y p e W i l d t y p e + m u t a n t M u t a n t W i l d t y p e W i l d t y p e + m u t a n t M u t a n t W i l d t y p e W i l d t y p e + m u t a n t M u t a n t W i l d t y p e W i l d t y p e + m u t a n t M u t a n t W i l d t y p e W i l d t y p e + m u t a n t M u t a n t A B C tion pathway was provided by the failure to detect b -catenin (stabilized by the activation of the WNT signaling pathway) in ovarian adenocarcinoma cells transfected with the mutant WNT4 (Fig. 3D ).
The genetic factors controlling development in female mammals remain mysterious. With the exception of translocations in SRY and mutations in steroidogenic enzymes, the genetic mechanisms that cause a phenotypic XX male or XX virilization are poorly understood. We determined the biologic consequences of a mutation in WNT4 and found that this gene appears to play a key role in human sexual differentiation.
The regression of the müllerian ducts in our patient suggests the occurrence in utero of ectopic ovarian expression of antimüllerian hormone , which is normally produced solely by testicular Sertoli cells at this stage of development. Furthermore, similar to Wnt4 -knockout female mice, our patient had clinical and biochemical signs of ectopic activation of androgenesis. The androgen excess appears mild, since her external genitalia were not virilized, a feature that again resembles the phenotype of Wnt4 -knockout female mice. We do not have direct proof that the mutation in WNT4 led to morphologic masculinization of the ovaries or loss of oocytes in our patient, since we did not analyze ovarian tissue. Nevertheless, the inability of the mutant WNT4 to inhibit the expression and activity of the steroidogenic enzymes in ovarian and adrenal cell lines provides good indirect evidence that the impairment of WNT4 signaling may have caused the androgen excess. Unlike the female Wnt4-knockout mice, 17 our patient did not have any defects in breast development, suggesting that this particular WNT4 mutation does not affect mammary-gland growth in women.
The mutant Glu226 residue in WNT4 in our patient (E226G) is conserved among species. However, other WNT proteins have different residues at that position, although never a glycine.
In searching for causes of the defective signaling, we found that the E226G mutant protein appears to be trapped inside the cell. The normal processing of WNT proteins is directly dependent on lipid modification. This apparently paradoxical phenomenon (cells have trouble releasing a molecule that is less hydrophobic than usual) is a very well known characteristic of WNT proteins and is probably due to misfolding of the protein during the formation of disulfide bonds between free cysteines. 16 The E226G mutation prevents lipid modification and therefore represents a mechanism underlying the transduction defect. The mutated glutamate is not located in a consensus palmitoylation site (residues 77 through 90), and it is thus more likely that the mutation leads to misfolding, retention of the protein in the endoplasmic reticulum, and a subsequent lack of palmitoylation. The reasons for the surprisingly efficient secretion of wild-type WNT4 are unclear, although we cannot exclude the possible involvement of the Xpress epitope. We obtained similar results in all functional assays when we evaluated the mutant and the wild-type WNT4 together. This finding suggests that the mutant WNT4 has dominant negative properties and provides a clear correlation between the genotype and the phenotype. However, the mechanism underlying such events remains unexplained, since WNT proteins do not seem to dimerize. 14 The loss-of-function mutation we identified in the WNT4 gene appears to cause developmental abnormalities in humans and indicates that WNT4 is a major player in the development and maintenance of the female phenotype in women, by virtue of its ability to regulate the formation of müllerian ducts and control steroidogenesis in the ovary. Any generalizations regarding its role, however, must await the description and characterization of mutations in additional patients.
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